Byetta Scripts, LAR Progress Unaffected By Safety Scare, Amylin Says
Executive Summary
FDA's review of a new monotherapy indication for Amylin's type 2 diabetes agent Byetta (exenatide) may provide the opportunity for updating the labeling to reflect a stronger warning on pancreatitis
You may also be interested in...
Amylin Speculation Intensifies: Byetta LAR May Be Delayed
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.
Biogen, Amylin Feel Impact Of Safety Scares; Another Wrinkle With TOUCH
Biogen Idec's landmark risk management program for Tysabri (natalizumab) is paying another dividend for the company: providing management with a credible source of data to reassure investors nervous about the commercial impact of newly reported cases of progressive multifocal leukoencephalopathy (PML) associated with the MS therapy
Biogen, Amylin Feel Impact Of Safety Scares; Another Wrinkle With TOUCH
Biogen Idec's landmark risk management program for Tysabri (natalizumab) is paying another dividend for the company: providing management with a credible source of data to reassure investors nervous about the commercial impact of newly reported cases of progressive multifocal leukoencephalopathy (PML) associated with the MS therapy